Although we established such a molecular classification for CNS DLBCL in present study, the underlying mechanism by which CD79B and PIM1 mutational status impact the outcome of primary CNS DLBCL after HD-MTX-based polychemotherapy remains unknown. This evidence concerns the gene PIM1 and diffuse large B-cell lymphoma of the central nervous system.